Handgrip  ||| S:0 E:9 ||| JJ
strength  ||| S:9 E:18 ||| NN
in  ||| S:18 E:21 ||| IN
men  ||| S:21 E:25 ||| NNS
with  ||| S:25 E:30 ||| IN
fibromyalgia  ||| S:30 E:43 ||| VBG
To  ||| S:43 E:46 ||| TO
examine  ||| S:46 E:54 ||| VB
the  ||| S:54 E:58 ||| DT
association  ||| S:58 E:70 ||| NN
of  ||| S:70 E:73 ||| IN
muscular  ||| S:73 E:82 ||| JJ
strength ||| S:82 E:90 ||| NN
,  ||| S:90 E:92 ||| ,
as  ||| S:92 E:95 ||| RB
measured  ||| S:95 E:104 ||| VBN
by  ||| S:104 E:107 ||| IN
handgrip  ||| S:107 E:116 ||| JJ
strength  ||| S:116 E:125 ||| NN
test  ||| S:125 E:130 ||| NN
( ||| S:130 E:131 ||| -LRB-
HGs ||| S:131 E:134 ||| NNP
) ||| S:134 E:135 ||| -RRB-
,  ||| S:135 E:137 ||| ,
with  ||| S:137 E:142 ||| IN
the  ||| S:142 E:146 ||| DT
presence ||| S:146 E:154 ||| NN
/ ||| S:154 E:155 ||| CD
absence  ||| S:155 E:163 ||| NN
of  ||| S:163 E:166 ||| IN
fibromyalgia  ||| S:166 E:179 ||| NNS
( ||| S:179 E:180 ||| -LRB-
FM ||| S:180 E:182 ||| NNP
)  ||| S:182 E:184 ||| -RRB-
and  ||| S:184 E:188 ||| CC
FM  ||| S:188 E:191 ||| JJ
severity  ||| S:191 E:200 ||| NN
in  ||| S:200 E:203 ||| IN
men ||| S:203 E:206 ||| NNS
.  ||| S:206 E:208 ||| .
A  ||| S:208 E:210 ||| DT
total  ||| S:210 E:216 ||| NN
of  ||| S:216 E:219 ||| IN
20  ||| S:219 E:222 ||| CD
men  ||| S:222 E:226 ||| NNS
( ||| S:226 E:227 ||| -LRB-
age ||| S:227 E:230 ||| NN
,  ||| S:230 E:232 ||| ,
( ||| S:232 E:233 ||| -LRB-
mean  ||| S:233 E:238 ||| VB
age±standard  ||| S:238 E:251 ||| CD
deviation ||| S:251 E:260 ||| NN
)  ||| S:260 E:262 ||| -RRB-
of  ||| S:262 E:265 ||| IN
48.0±8.0  ||| S:265 E:274 ||| CD
years ||| S:274 E:279 ||| NNS
)  ||| S:279 E:281 ||| -RRB-
with  ||| S:281 E:286 ||| IN
FM  ||| S:286 E:289 ||| NNP
and  ||| S:289 E:293 ||| CC
60  ||| S:293 E:296 ||| CD
healthy  ||| S:296 E:304 ||| JJ
subjects  ||| S:304 E:313 ||| NNS
( ||| S:313 E:314 ||| -LRB-
age ||| S:314 E:317 ||| NN
,  ||| S:317 E:319 ||| ,
49.5±7.3  ||| S:319 E:328 ||| CD
years ||| S:328 E:333 ||| NNS
)  ||| S:333 E:335 ||| -RRB-
participated  ||| S:335 E:348 ||| VBD
in  ||| S:348 E:351 ||| IN
the  ||| S:351 E:355 ||| DT
study ||| S:355 E:360 ||| NN
.  ||| S:360 E:362 ||| .
The  ||| S:362 E:366 ||| DT
HGs  ||| S:366 E:370 ||| NN
was  ||| S:370 E:374 ||| VBD
measured  ||| S:374 E:383 ||| VBN
by  ||| S:383 E:386 ||| IN
a  ||| S:386 E:388 ||| DT
maximal  ||| S:388 E:396 ||| JJ
isometric  ||| S:396 E:406 ||| JJ
test  ||| S:406 E:411 ||| NN
using  ||| S:411 E:417 ||| VBG
a  ||| S:417 E:419 ||| DT
dynamometer  ||| S:419 E:431 ||| NN
with  ||| S:431 E:436 ||| IN
adjustable  ||| S:436 E:447 ||| JJ
grip  ||| S:447 E:452 ||| NN
in  ||| S:452 E:455 ||| IN
both  ||| S:455 E:460 ||| DT
hands ||| S:460 E:465 ||| NNS
,  ||| S:465 E:467 ||| ,
and  ||| S:467 E:471 ||| CC
the  ||| S:471 E:475 ||| DT
average  ||| S:475 E:483 ||| JJ
score  ||| S:483 E:489 ||| NN
was  ||| S:489 E:493 ||| VBD
used  ||| S:493 E:498 ||| VBN
in  ||| S:498 E:501 ||| IN
the  ||| S:501 E:505 ||| DT
analysis ||| S:505 E:513 ||| NN
.  ||| S:513 E:515 ||| .
All  ||| S:515 E:519 ||| DT
FM  ||| S:519 E:522 ||| JJ
patients  ||| S:522 E:531 ||| NNS
completed  ||| S:531 E:541 ||| VBD
the  ||| S:541 E:545 ||| DT
Spanish  ||| S:545 E:553 ||| JJ
version  ||| S:553 E:561 ||| NN
of  ||| S:561 E:564 ||| IN
the  ||| S:564 E:568 ||| DT
Fibromyalgia  ||| S:568 E:581 ||| NNP
Impact  ||| S:581 E:588 ||| NNP
Questionnaire  ||| S:588 E:602 ||| NNP
( ||| S:602 E:603 ||| -LRB-
FIQ ||| S:603 E:606 ||| NNP
) ||| S:606 E:607 ||| -RRB-
.  ||| S:607 E:609 ||| .
Patients  ||| S:609 E:618 ||| NNS
were  ||| S:618 E:623 ||| VBD
classified  ||| S:623 E:634 ||| VBN
as  ||| S:634 E:637 ||| IN
having  ||| S:637 E:644 ||| VBG
moderate  ||| S:644 E:653 ||| JJ
FM  ||| S:653 E:656 ||| NN
if  ||| S:656 E:659 ||| IN
the  ||| S:659 E:663 ||| DT
FIQ  ||| S:663 E:667 ||| NNP
was  ||| S:667 E:671 ||| VBD
< ||| S:671 E:672 ||| SYM
70  ||| S:672 E:675 ||| CD
and  ||| S:675 E:679 ||| CC
as  ||| S:679 E:682 ||| IN
having  ||| S:682 E:689 ||| VBG
severe  ||| S:689 E:696 ||| JJ
FM  ||| S:696 E:699 ||| NN
if  ||| S:699 E:702 ||| IN
the  ||| S:702 E:706 ||| DT
FIQ  ||| S:706 E:710 ||| NNP
was  ||| S:710 E:714 ||| VBD
≥70 ||| S:714 E:717 ||| CD
.  ||| S:717 E:719 ||| .
HGs  ||| S:719 E:723 ||| NNP
was  ||| S:723 E:727 ||| VBD
~17 ||| S:727 E:730 ||| CD
%  ||| S:730 E:732 ||| NN
lower  ||| S:732 E:738 ||| JJR
in  ||| S:738 E:741 ||| IN
FM  ||| S:741 E:744 ||| JJ
patients  ||| S:744 E:753 ||| NNS
compared  ||| S:753 E:762 ||| VBN
to  ||| S:762 E:765 ||| TO
healthy  ||| S:765 E:773 ||| JJ
men  ||| S:773 E:777 ||| NNS
( ||| S:777 E:778 ||| -LRB-
p=0.005 ||| S:778 E:785 ||| NNP
)  ||| S:785 E:787 ||| -RRB-
and  ||| S:787 E:791 ||| CC
~27 ||| S:791 E:794 ||| CD
%  ||| S:794 E:796 ||| NN
lower  ||| S:796 E:802 ||| JJR
in  ||| S:802 E:805 ||| IN
men  ||| S:805 E:809 ||| NNS
with  ||| S:809 E:814 ||| IN
severe  ||| S:814 E:821 ||| JJ
FM  ||| S:821 E:824 ||| NN
compared  ||| S:824 E:833 ||| VBN
to  ||| S:833 E:836 ||| TO
those  ||| S:836 E:842 ||| DT
with  ||| S:842 E:847 ||| IN
moderate  ||| S:847 E:856 ||| JJ
FM  ||| S:856 E:859 ||| NNP
( ||| S:859 E:860 ||| -LRB-
p=0.03 ||| S:860 E:866 ||| NNP
) ||| S:866 E:867 ||| -RRB-
.  ||| S:867 E:869 ||| .
Age-adjusted  ||| S:869 E:882 ||| JJ
logistic  ||| S:882 E:891 ||| JJ
regression  ||| S:891 E:902 ||| JJ
models  ||| S:902 E:909 ||| NNS
showed  ||| S:909 E:916 ||| VBD
that  ||| S:916 E:921 ||| IN
1  ||| S:921 E:923 ||| CD
kilogram  ||| S:923 E:932 ||| JJ
increment  ||| S:932 E:942 ||| NN
in  ||| S:942 E:945 ||| IN
HGs  ||| S:945 E:949 ||| NNP
was  ||| S:949 E:953 ||| VBD
associated  ||| S:953 E:964 ||| VBN
with  ||| S:964 E:969 ||| IN
an  ||| S:969 E:972 ||| DT
8 ||| S:972 E:973 ||| CD
%  ||| S:973 E:975 ||| NN
reduced  ||| S:975 E:983 ||| VBN
risk  ||| S:983 E:988 ||| NN
of  ||| S:988 E:991 ||| IN
having  ||| S:991 E:998 ||| VBG
FM  ||| S:998 E:1001 ||| NNP
( ||| S:1001 E:1002 ||| -LRB-
OR=0.92 ||| S:1002 E:1009 ||| NNP
,  ||| S:1009 E:1011 ||| ,
95 ||| S:1011 E:1013 ||| CD
%  ||| S:1013 E:1015 ||| NN
CI ||| S:1015 E:1017 ||| NNP
:  ||| S:1017 E:1019 ||| :
0.86-0.97 ||| S:1019 E:1028 ||| CD
,  ||| S:1028 E:1030 ||| ,
p=0.002 ||| S:1030 E:1037 ||| CD
) ||| S:1037 E:1038 ||| -RRB-
.  ||| S:1038 E:1040 ||| .
In  ||| S:1040 E:1043 ||| IN
the  ||| S:1043 E:1047 ||| DT
FM  ||| S:1047 E:1050 ||| JJ
group ||| S:1050 E:1055 ||| NN
,  ||| S:1055 E:1057 ||| ,
1  ||| S:1057 E:1059 ||| CD
kilogram  ||| S:1059 E:1068 ||| JJ
increment  ||| S:1068 E:1078 ||| NN
in  ||| S:1078 E:1081 ||| IN
HGs  ||| S:1081 E:1085 ||| NNP
was  ||| S:1085 E:1089 ||| VBD
associated  ||| S:1089 E:1100 ||| VBN
with  ||| S:1100 E:1105 ||| IN
a  ||| S:1105 E:1107 ||| DT
13 ||| S:1107 E:1109 ||| CD
%  ||| S:1109 E:1111 ||| NN
reduced  ||| S:1111 E:1119 ||| VBN
risk  ||| S:1119 E:1124 ||| NN
for  ||| S:1124 E:1128 ||| IN
having  ||| S:1128 E:1135 ||| VBG
severe  ||| S:1135 E:1142 ||| JJ
FM  ||| S:1142 E:1145 ||| NNP
( ||| S:1145 E:1146 ||| -LRB-
OR=0.87 ||| S:1146 E:1153 ||| NNP
,  ||| S:1153 E:1155 ||| ,
95 ||| S:1155 E:1157 ||| CD
%  ||| S:1157 E:1159 ||| NN
CI ||| S:1159 E:1161 ||| NNP
:  ||| S:1161 E:1163 ||| :
0.76-0.99 ||| S:1163 E:1172 ||| CD
,  ||| S:1172 E:1174 ||| ,
p=0.04 ||| S:1174 E:1180 ||| CD
) ||| S:1180 E:1181 ||| -RRB-
.  ||| S:1181 E:1183 ||| .
HGs  ||| S:1183 E:1187 ||| NNP
was  ||| S:1187 E:1191 ||| VBD
negatively  ||| S:1191 E:1202 ||| RB
associated  ||| S:1202 E:1213 ||| VBN
with  ||| S:1213 E:1218 ||| IN
pain ||| S:1218 E:1222 ||| NN
,  ||| S:1222 E:1224 ||| ,
fatigue ||| S:1224 E:1231 ||| NN
,  ||| S:1231 E:1233 ||| ,
stiffness  ||| S:1233 E:1243 ||| NN
and  ||| S:1243 E:1247 ||| CC
with  ||| S:1247 E:1252 ||| IN
the  ||| S:1252 E:1256 ||| DT
total  ||| S:1256 E:1262 ||| JJ
score  ||| S:1262 E:1268 ||| NN
from  ||| S:1268 E:1273 ||| IN
the  ||| S:1273 E:1277 ||| DT
FIQ  ||| S:1277 E:1281 ||| NNP
( ||| S:1281 E:1282 ||| -LRB-
all  ||| S:1282 E:1286 ||| DT
p  ||| S:1286 E:1287 ||| JJ
< ||| S:1287 E:1288 ||| SYM
0.05 ||| S:1288 E:1292 ||| CD
) ||| S:1292 E:1293 ||| -RRB-
.  ||| S:1293 E:1295 ||| .
HGs  ||| S:1295 E:1299 ||| NNP
is  ||| S:1299 E:1302 ||| VBZ
reduced  ||| S:1302 E:1310 ||| VBN
in  ||| S:1310 E:1313 ||| IN
male  ||| S:1313 E:1318 ||| JJ
FM  ||| S:1318 E:1321 ||| JJ
patients  ||| S:1321 E:1330 ||| NNS
and  ||| S:1330 E:1334 ||| CC
is  ||| S:1334 E:1337 ||| VBZ
inversely  ||| S:1337 E:1347 ||| RB
related  ||| S:1347 E:1355 ||| VBN
to  ||| S:1355 E:1358 ||| TO
FM  ||| S:1358 E:1361 ||| JJ
severity  ||| S:1361 E:1370 ||| NN
and  ||| S:1370 E:1374 ||| CC
symptomatology ||| S:1374 E:1388 ||| NN
.  ||| S:1388 E:1390 ||| .
HGs  ||| S:1390 E:1394 ||| JJ
testing  ||| S:1394 E:1402 ||| NN
could  ||| S:1402 E:1408 ||| MD
be  ||| S:1408 E:1411 ||| VB
used  ||| S:1411 E:1416 ||| VBN
as  ||| S:1416 E:1419 ||| IN
a  ||| S:1419 E:1421 ||| DT
complementary  ||| S:1421 E:1435 ||| JJ
tool  ||| S:1435 E:1440 ||| NN
in  ||| S:1440 E:1443 ||| IN
the  ||| S:1443 E:1447 ||| DT
assessment  ||| S:1447 E:1458 ||| NN
and  ||| S:1458 E:1462 ||| CC
monitoring  ||| S:1462 E:1473 ||| NN
of  ||| S:1473 E:1476 ||| IN
FM ||| S:1476 E:1478 ||| NNP
.  ||| S:1478 E:1480 ||| .
Further  ||| S:1480 E:1488 ||| JJ
research  ||| S:1488 E:1497 ||| NN
on  ||| S:1497 E:1500 ||| IN
male  ||| S:1500 E:1505 ||| JJ
FM  ||| S:1505 E:1508 ||| JJ
patients  ||| S:1508 E:1517 ||| NNS
is  ||| S:1517 E:1520 ||| VBZ
needed  ||| S:1520 E:1527 ||| VBN
to  ||| S:1527 E:1530 ||| TO
confirm  ||| S:1530 E:1538 ||| VB
or  ||| S:1538 E:1541 ||| CC
contrast  ||| S:1541 E:1550 ||| NN
these  ||| S:1550 E:1556 ||| DT
findings ||| S:1556 E:1564 ||| NNS
.  ||| S:1564 E:1566 ||| .
